Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide once weekly for Parkinson's disease
2018-003028-35Phase 3Unknown
- Sponsor
- UCL Comprehensive Clinical Trials Unit
- Start
- Nov 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Bydureon once weekly with Placebo once weekly (2 arms). Primary endpoint: MDS-UPDRS part 3 motor sub-score at 96 weeks. Status: unknown.
02
Drugs
exenatide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2018-003028-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003028-35.